Long-term consequences of peritonitis

Peritoneal Dialysis International

Volumn 16, Issue SUPPL. 1, 1996, Pages

  Boeschoten, Elisabeth W ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Found Home Dialysis Midden W N   (Netherlands)

Author keywords

Long term; Peritoneal membrane; Peritonitis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; CEFRADINE; CEPHALOSPORIN; GENTAMICIN; METICILLIN; VANCOMYCIN;

CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; GRAM POSITIVE BACTERIUM; HEARING LOSS; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY FAILURE; MORTALITY; NEPHROTOXICITY; OTOTOXICITY; PERITONEAL CATHETER; PERITONITIS; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME;

EID: 0029940460     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089601601s67     Document Type: Conference Paper

References (43)

1. Keane WF, Vas SI. Peritonitis. In: Gokal R, Nolph KD, eds. The textbook of peritoneal dialysis. Dordrecht: Kluwer Academic Publishers, 1994:473-501.
2. Gokal R, Jakubowski C, King J, et al. Outcome in patients on continuous ambulatory peritoneal dialysis and haemodialysis: 4-year analysis of a prospective multicentre study. Lancet 1987; ii:1105-9.
3. Serkes KD, Blagg CR, Nolph KD, et al. Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: a multicentre study. Perit Dial Int 1990; 10:15-19.
4. Maiorca R, Cancarini GC, Brunori G, et al. Morbidity and mortality of CAPD and hemodialysis. Kidney Int 1993; 43(Suppl 40):S4-S15.
5. Swartz RD. Chronic peritoneal dialysis: mechanical and infectious complications.Nephron 1985;40:20-37.
6. Gloor HJ, Nichols UK, Sorkin MI, et al. Peritoneal access and related complications in continuous ambulatory peritoneal dialysis. Am J Med 1983; 74:593-8.
7. Bernardini J, Holley JL, Johnston JR, et al. An analysis of infections in adults on continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1991; 36:29-34.
8. Maiorca R, Cancarini GC, Manili L, et al. Peritonitis rate and CAPD results. In: La Greca G, Ronco C, Feriani M, Chiaramonte S, Conz P, eds. Peritoneal dialysis. Milano: Wichtig Editore, 1991:223-31.
9. Fenton SSA. Peritonitis-related deaths among CAPD patients. Perit Dial Bull 1983; 3:9-11.
10. Digenis GE, Abraham G, Savin E, et al. Peritonitisrelated deaths in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1990; 10:45-7.
11. Tzamaloukas AH, Obermiller LE, Gibel LJ, et al. Peritonitis associated with intra-abdominal pathology in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13(Suppl 2):S335-7.
12. Wakeen MJ, Zimmerman SW, Bidwell D. Viscus perforation in peritoneal dialysis patients: diagnosis and outcome. Perit Dial Int 1994; 14:371-7.
13. Tranaeus A, Heimbürger O, Lindholm B. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): diagnostic findings, therapeutic outcome and complications. Perit Dial Int 1989; 9:179-90.
14. Gregory MC, Duffy DP. Toxic shock following staphylococcal peritonitis. Clin Nephrol 1983; 20:101-4.
15. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif 1989; 7:74-85.
16. Gandhi VC, Huamyun HM, Ing TS, et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980; 140:1201-3.
17. Krediet RT, Struijk DG, Boeschoten EW, et al. The time course of peritoneal transport kinetics in continuous ambulatory peritoneal dialysis patients who develop sclerosing peritonitis. Am J Kidney Dis 1989; 13:299-307.
18. Pusateri R, Ross R, Marshall R, et al. Sclerosing encapsulating peritonitis: report of a case with small bowel obstruction managed by long-term home parenteral hyperalimentation, and a review of the literature. Am J Kidney Dis 1986; 8:56-60.
19. Oulès R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3:66-9.
20. Slingeneyer A. Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. Contrib Nephrol 1987; 57:239-47.
21. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14-27.
22. Rottembourg J, Issad B, Langlois P, et al. Sclerosing encapsulating peritonitis during CAPD. Evaluation of the potential risk factors. In: Maher JF, Winchester JF, eds. Frontiers in peritoneal dialysis. New York: Field, Rich and Assoc. Inc., 1986:643-9.
23. Lo WK, Chan KT, Leung ALT, et al. Sclerosing peritonitis complicating prolonged use of chlorhexidine in alcohol in the connection procedure for continuous ambulatory peritoneal dialysis. Perit Dial Int 1991; 11:166-72.
24. Bargman JM. Noninfectious complications of peritoneal dialysis. In: Gokal R, Nolph KD, eds. The textbook of peritoneal dialysis. Dordrecht: Kluwer Academic Publishers, 1994:473-501.
25. Johnson CA. Intraperitoneal vancomycin administration. Perit Dial Int 1991; 11:9-11.
26. Freiman JP, Graham DJ, Reed TG, et al. Chemical peritonitis following the intraperitoneal administration of vancomycin. Perit Dial Int 1992; 12:57-60.
27. Struijk DG, Krediet RT, Boeschoten EW, et al. Antifungal treatment of Candida peritonitis in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1987; 9:66-70.
28. Sitter T, Spannagl M, Schiffl H, et al. Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of A mesothelial cells. Nephrol Dial Transplant 1995; 10:677-83.
29. Vipond MN, Whawell SA, Thompson JN. Peritoneal fibrinolytic activity and intra-abdominal adhesions. Lancet 1990; i:1120-2.
30. Boeschoten EW. Peritonitis in CAPD; changes in causative micro-organisms and antimicrobial resistance. In: La Greca G, Ronco C, Feriani M, Chiaramonte S, Conz P, eds. Peritoneal dialysis. Milano: Wichtig Editore, 1991:247-57.
31. Maiorca R, Cantaluppi A, Cancarini GC, et al. Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis. Lancet 1983; ii:644-52.
32. Maiorca R, Cancarini GC, Brasa S,et al. Y-system with disinfectant in the prevention of peritonitis in CAPD. Contrib Nephrol 1987; 17:178-84.
33. Canadian CAPD Clinical Trials Group. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multicenter randomized clinical trial comparing the Y connector disinfectant system to standard systems. Perit Dial Int 1989; 9:159-63.
34. Port FK, Held PJ, Nolph KD, et al. Risk of peritonitis and technique failure by CAPD connection technique: a national study. Kidney Int 1992; 42:967-74.
35. Rottembourg J, Brouard R, Issad B, et al. Prospective randomized study about Y connectors in CAPD patients. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in continuous ambulatory peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin Inc., 1987:107-13.
36. Keane WF, Everett ED, Golper TA, et al. Peritoneal dialysis-related peritonitis treatment recommendations 1993 update. Perit Dial Int 1993; 13:14-28.
37. Zimmerman SW, O'Brien M, Wiedenhoeft FA, et al. Staphylococcus aureus peritoneal catheter-related infections: a cause of catheter loss and peritonitis. Perit Dial Int 1988; 8:191-4.
38. Luzar MA, Coles GA, Faller B, et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322:505-9.
39. Churchill DN. CAPD peritonitis: a critical appraisal of prophylactic strategies. Semin Dial 1991; 4:94-100.
40. Atkins RC, Humphery T, Thomson N, et al. Efficacy of treatment in CAPD peritonitis - the problem of staphylococcal antibiotic resistance. In: Atkins RC, Thomson NM, Farrell PC, eds. Peritoneal dialysis. Edinburgh: Churchill Livingstone 1981:337-9.
41. Chong TK, Piraino B, Bemardini J. Vestibular toxicity due to gentamicin in peritoneal dialysis patients. Perit Dial Int 1991; 11:152-5.
42. Nikolaidis P, Vas S, Lawson V, et al. Is intraperitoneal tobramycin ototoxic in CAPD patients? Perit Dial Int 1991; 11:156-61.
43. Van der Hulst RJ, Boeschoten EW, Nielsen FW, et al. Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. Oto Rhino Laryngology 1991; 53:19-23.